Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Policy / Regulatory

Guangzhou Boosts Innovative Drug Development with New HSA Initiatives

Fineline Cube May 24, 2024

The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...

Company Drug

Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico

Fineline Cube May 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition

Fineline Cube May 24, 2024

Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with...

Company Drug

Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China

Fineline Cube May 24, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study

Fineline Cube May 24, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...

Company Deals

Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab

Fineline Cube May 24, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking...

Company Deals

Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals

Fineline Cube May 23, 2024

Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...

Company Deals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

Fineline Cube May 23, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...

Company Deals

Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03

Fineline Cube May 23, 2024

Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...

Company Deals

Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement

Fineline Cube May 23, 2024

China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...

Policy / Regulatory

China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations

Fineline Cube May 23, 2024

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...

Company

Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary

Fineline Cube May 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...

Company Drug

Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...

Company Drug

Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment

Fineline Cube May 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...

Company Drug

NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment

Fineline Cube May 23, 2024

NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...

Company Deals Digital

C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain

Fineline Cube May 23, 2024

C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...

Company Deals

AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement

Fineline Cube May 23, 2024

HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...

Company Deals

Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...

Company Drug

Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval

Fineline Cube May 23, 2024

Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial

Fineline Cube May 23, 2024

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based...

Posts pagination

1 … 357 358 359 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.